1.36
-0.0701(-4.90%)
Currency In USD
| Previous Close | 1.43 |
| Open | 1.38 |
| Day High | 1.4 |
| Day Low | 1.33 |
| 52-Week High | 19.51 |
| 52-Week Low | 0.51 |
| Volume | 31,843 |
| Average Volume | 159,306 |
| Market Cap | 47.3M |
| PE | -7.56 |
| EPS | -0.18 |
| Moving Average 50 Days | 1.5 |
| Moving Average 200 Days | 1.18 |
| Change | -0.07 |
If you invested $1000 in JUPITER NEUROSCIENCES, INC. (JUNS) since IPO date, it would be worth $0 as of November 03, 2025 at a share price of $1.36. Whereas If you bought $1000 worth of JUPITER NEUROSCIENCES, INC. (JUNS) shares 0 years ago, it would be worth $247.7 as of November 03, 2025 at a share price of $1.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
GlobeNewswire Inc.
Oct 27, 2025 12:30 PM GMT
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc (“JUNS” or the “Company”) (NASDAQ: JUNS), a clinical stage biopharmaceuti
Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador
GlobeNewswire Inc.
Sep 15, 2025 12:00 PM GMT
Partnership strengthens Nugevia™ launch bringing clinical and scientific integrity to the fast-growing longevity space Jupiter, Florida, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Jean Fallaca
Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
GlobeNewswire Inc.
Aug 26, 2025 12:00 PM GMT
Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company pioneering therapies for centr